Hangzhou Minsheng Health Second Phase Share Repurchase Progress: A total of 2.11M shares repurchased, costing 31.4766 million yuan

Log in to Sina Finance APP and search for [Information Disclosure] to see more evaluation levels

On April 3rd, Hangzhou Minsheng Health Pharmaceutical Co., Ltd. (hereinafter referred to as “Hangzhou Minsheng Health”) released the progress announcement of the second phase of share repurchase through centralized bidding trading. The announcement shows that as of March 31, 2026, the company has repurchased a total of 2.11M shares, accounting for 0.59% of the total share capital, with a total payment of 31.4766 million yuan (excluding transaction fees).

Background of the Repurchase Plan

Hangzhou Minsheng Health held the 11th meeting of the second board of directors on October 28, 2025, and approved the second phase of the share repurchase plan. According to the plan, the company intends to use its own funds to repurchase shares through centralized bidding trading for equity incentives. The repurchase price shall not exceed 21.06 yuan per share (which is 150% of the average trading price of the company’s stock in the thirty trading days before the board’s approval of the repurchase resolution), with an estimated repurchase of 2.1 million to 2.4 million shares, and a total repurchase fund not exceeding 2.11M yuan. The implementation period for the repurchase is within 12 months from the date of board approval (i.e., until October 28, 2026).

Details of the Repurchase Progress

As of March 31, 2026, the specific implementation of Hangzhou Minsheng Health’s second phase of share repurchase is as follows:

The announcement points out that this share repurchase complies with relevant laws, regulations, and the company’s established repurchase plan. From the price perspective, the actual repurchase price range (14.22 yuan/share - 15.67 yuan/share) is far below the upper limit of 21.06 yuan/share, indicating that the company conducted repurchase operations when market prices were relatively low.

Compliance Explanation

Hangzhou Minsheng Health emphasizes that this repurchase strictly complies with the “Guidelines for Self-Regulation of Listed Companies on the Shenzhen Stock Exchange No. 9 — Repurchase of Shares” and relevant provisions of the company’s repurchase plan. Specifically: no repurchase of shares occurred during major events or decision-making processes that could significantly impact the company’s securities trading price, nor before the legal disclosure date; when repurchasing through centralized bidding, the entrusted price was not at the daily trading limit price, and no entrustment was made during opening call auctions, closing call auctions, or trading days without price limits.

Follow-up Plan

The company states that it will continue to implement this repurchase plan within the repurchase period based on market conditions, and will fulfill information disclosure obligations in a timely manner according to relevant laws and regulations. Investors are advised to pay attention to investment risks.

This share repurchase reflects Hangzhou Minsheng Health’s confidence in the company’s future development. By repurchasing shares for equity incentives, it helps to further improve the company’s governance structure, motivate the core team, and lay a foundation for the company’s long-term development.

Disclaimer: The market has risks; investment should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. All information appearing in this article is for reference only and does not constitute personal investment advice. For discrepancies, please refer to the actual announcement. If you have questions, please contact biz@staff.sina.com.cn.

Click to view the original announcement>>

Massive information, precise interpretation, all on Sina Finance APP

Editor: Xiao Lang Express